CGS 32359Alternative Names: C5aRAD
Latest Information Update: 20 Aug 2002
At a glance
- Originator Novartis
- Class Anti-ischaemics
- Mechanism of Action Complement C5a inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Reperfusion injury